JP6049625B2 - 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 - Google Patents

様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 Download PDF

Info

Publication number
JP6049625B2
JP6049625B2 JP2013535439A JP2013535439A JP6049625B2 JP 6049625 B2 JP6049625 B2 JP 6049625B2 JP 2013535439 A JP2013535439 A JP 2013535439A JP 2013535439 A JP2013535439 A JP 2013535439A JP 6049625 B2 JP6049625 B2 JP 6049625B2
Authority
JP
Japan
Prior art keywords
insulin
intervals
average
glu
des
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013535439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500244A (ja
JP2014500244A5 (enExample
Inventor
シュー・ヨハンセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority claimed from PCT/EP2011/068870 external-priority patent/WO2012055967A2/en
Publication of JP2014500244A publication Critical patent/JP2014500244A/ja
Publication of JP2014500244A5 publication Critical patent/JP2014500244A5/ja
Application granted granted Critical
Publication of JP6049625B2 publication Critical patent/JP6049625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2013535439A 2010-10-27 2011-10-27 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 Active JP6049625B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40720610P 2010-10-27 2010-10-27
EP11170366 2010-10-27
EP10189115 2010-10-27
EP11170366.6 2010-10-27
US61/407,206 2010-10-27
EP10189115.8 2010-10-27
US201161498645P 2011-06-20 2011-06-20
US61/498,645 2011-06-20
PCT/EP2011/068870 WO2012055967A2 (en) 2010-10-27 2011-10-27 Treating diabetes melitus using insulin injections administered with varying injection intervals

Publications (3)

Publication Number Publication Date
JP2014500244A JP2014500244A (ja) 2014-01-09
JP2014500244A5 JP2014500244A5 (enExample) 2014-12-04
JP6049625B2 true JP6049625B2 (ja) 2016-12-21

Family

ID=50036508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013535439A Active JP6049625B2 (ja) 2010-10-27 2011-10-27 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療

Country Status (6)

Country Link
US (1) US10596229B2 (enExample)
JP (1) JP6049625B2 (enExample)
BR (1) BR112013010345A2 (enExample)
DK (1) DK2632478T3 (enExample)
HR (1) HRP20191793T1 (enExample)
RU (1) RU2013123515A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
EP0174493B1 (de) 1984-08-17 1988-05-25 Bayer Ag Thermoplastische Formmassen mit flammwidrigen Eigenschaften
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK45590D0 (enExample) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
DE69232847T2 (de) 1991-12-20 2003-09-11 Novo Nordisk A/S, Bagsvaerd Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
CZ289343B6 (cs) 1995-03-17 2002-01-16 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek pro léčení diabetes
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
PT821006E (pt) 1996-07-26 2004-09-30 Aventis Pharma Gmbh Derivados de insulina com ligacao a zinco aumentada
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP2001518915A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ インシュリンと吸収増強剤の共沈殿による治療用粉末の調整法
JP2001518916A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ 結晶インスリンを含有する肺投与のための治療用粉末調合物
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
RU2218349C2 (ru) 1997-10-24 2003-12-10 Ново Нордиск А/С Агрегаты производных инсулина человека
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
UA65636C2 (uk) 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
WO2000043034A2 (en) 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES WITH EXTENDED CIRCULAR HALF TIME
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
JP5599543B2 (ja) 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
RU2329823C2 (ru) 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CN1771040B (zh) 2003-02-07 2010-06-16 味之素株式会社 糖尿病治疗药
CN100422328C (zh) 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135
BRPI0408105A (pt) 2003-03-04 2006-03-01 Thetechnology Dev Company Ltd sistema de distribuição para droga e terapia celular
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
WO2005063298A1 (en) 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
CA2567309A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
CA2576519C (en) 2004-08-17 2013-05-21 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
EP2012817A2 (en) 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2217621B1 (en) 2007-11-08 2015-04-22 Novo Nordisk A/S Insulin derivative
BRPI0820535B8 (pt) 2007-11-16 2021-05-25 Novo Nordisk As composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
MX2012012943A (es) 2010-05-10 2012-11-29 Novo Nordisk As Proceso para preparacion de complejos de insulina-cinc.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
EP4070801A1 (en) 2011-03-01 2022-10-12 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
EP2798546B1 (en) 2011-09-13 2020-12-23 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP2844274B1 (en) 2012-05-01 2019-03-20 Novo Nordisk A/S Pharmaceutical composition
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime

Also Published As

Publication number Publication date
JP2014500244A (ja) 2014-01-09
DK2632478T3 (da) 2019-10-07
HRP20191793T1 (hr) 2019-12-27
BR112013010345A2 (pt) 2017-07-25
US10596229B2 (en) 2020-03-24
RU2013123515A (ru) 2014-12-10
US20180125946A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
JP5814525B2 (ja) 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
EP2632478B1 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
US10137172B2 (en) Administration regime
JP6755175B2 (ja) インスリン投薬レジメン
JP6262206B2 (ja) 医薬組成物
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
ES2749382T3 (es) Tratamiento de la diabetes mellitus mediante el uso de inyecciones de insulina administradas con intervalos de inyección variables

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161122

R150 Certificate of patent or registration of utility model

Ref document number: 6049625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250